CANY
FOLD

Caxton Associates (New York)’s Amicus Therapeutics FOLD Stock Holding History

Caxton Associates (New York)’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-17,870
Closed -$174K – 464
2019
Q4 		$174K Buy
+17,870
New +$164K 0.02% 366

Other funds holding FOLD

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Caxton Associates (New York)'s FOLD Position: Q1 2020 in Review

Caxton Associates (New York) sold out of Amicus Therapeutics (FOLD) in Q1 2020, closing a stake of 17,870 shares — an estimated $174K sold.

Caxton Associates (New York) first reported a position in FOLD in Q4 2019 and held it in 1 quarter. The position peaked at $174K in Q4 2019. 203 funds tracked by Wall St. Rank hold FOLD as of Q1 2020.

  • Caxton Associates (New York) reported no remaining Amicus Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Caxton Associates (New York) sold 17,870 Amicus Therapeutics shares in Q1 2020, an estimated $174K.
  • Caxton Associates (New York) first reported a position in Amicus Therapeutics in Q4 2019 and held it in 1 quarter.
  • Caxton Associates (New York)'s Amicus Therapeutics position peaked at $174K in Q4 2019.
  • 203 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2020.

Based on Caxton Associates (New York)'s 13F filing for Q1 2020, filed 15 May 2020.